JP2015505477A - Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 - Google Patents

Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 Download PDF

Info

Publication number
JP2015505477A
JP2015505477A JP2014555736A JP2014555736A JP2015505477A JP 2015505477 A JP2015505477 A JP 2015505477A JP 2014555736 A JP2014555736 A JP 2014555736A JP 2014555736 A JP2014555736 A JP 2014555736A JP 2015505477 A JP2015505477 A JP 2015505477A
Authority
JP
Japan
Prior art keywords
human
mouse
gene
immunoglobulin
adam6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014555736A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505477A5 (OSRAM
Inventor
リン マクドナルド，
リン マクドナルド，
ケーガン グーラー，
ケーガン グーラー，
カロライナ エー． ミーガー，
カロライナ エー． ミーガー，
ショーン スティーブンス，
ショーン スティーブンス，
アンドリュー ジェイ． マーフィー，
アンドリュー ジェイ． マーフィー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2015505477A publication Critical patent/JP2015505477A/ja
Publication of JP2015505477A5 publication Critical patent/JP2015505477A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24046—Adamalysin (3.4.24.46)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Central Heating Systems (AREA)
  • Housing For Livestock And Birds (AREA)
JP2014555736A 2012-02-01 2013-02-01 Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物 Withdrawn JP2015505477A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261593463P 2012-02-01 2012-02-01
US61/593,463 2012-02-01
US201261677538P 2012-07-31 2012-07-31
US61/677,538 2012-07-31
PCT/US2013/024295 WO2013116609A1 (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018022012A Division JP6698718B2 (ja) 2012-02-01 2018-02-09 Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物

Publications (2)

Publication Number Publication Date
JP2015505477A true JP2015505477A (ja) 2015-02-23
JP2015505477A5 JP2015505477A5 (OSRAM) 2016-03-03

Family

ID=47714588

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2014555736A Withdrawn JP2015505477A (ja) 2012-02-01 2013-02-01 Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物
JP2018022012A Active JP6698718B2 (ja) 2012-02-01 2018-02-09 Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物
JP2019130027A Active JP6942757B2 (ja) 2012-02-01 2019-07-12 Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物
JP2021099420A Active JP7187615B2 (ja) 2012-02-01 2021-06-15 Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物
JP2022191963A Active JP7525579B2 (ja) 2012-02-01 2022-11-30 Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物
JP2023173593A Pending JP2023168590A (ja) 2012-02-01 2023-10-05 Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2018022012A Active JP6698718B2 (ja) 2012-02-01 2018-02-09 Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物
JP2019130027A Active JP6942757B2 (ja) 2012-02-01 2019-07-12 Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物
JP2021099420A Active JP7187615B2 (ja) 2012-02-01 2021-06-15 Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物
JP2022191963A Active JP7525579B2 (ja) 2012-02-01 2022-11-30 Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物
JP2023173593A Pending JP2023168590A (ja) 2012-02-01 2023-10-05 Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物

Country Status (26)

Country Link
US (3) US20130212719A1 (OSRAM)
EP (3) EP3597038B1 (OSRAM)
JP (6) JP2015505477A (OSRAM)
KR (2) KR20190006029A (OSRAM)
CN (2) CN104202971B (OSRAM)
AU (3) AU2013204758B2 (OSRAM)
BR (1) BR112014018843B1 (OSRAM)
CA (1) CA2863175A1 (OSRAM)
CY (2) CY1122419T1 (OSRAM)
DK (2) DK2809150T3 (OSRAM)
ES (2) ES2753774T3 (OSRAM)
HR (2) HRP20192218T1 (OSRAM)
HU (2) HUE046744T2 (OSRAM)
IL (3) IL233827A0 (OSRAM)
LT (2) LT3597038T (OSRAM)
ME (1) ME03611B (OSRAM)
MX (2) MX373286B (OSRAM)
NZ (5) NZ734504A (OSRAM)
PL (2) PL2809150T3 (OSRAM)
PT (2) PT3597038T (OSRAM)
RS (2) RS62023B1 (OSRAM)
RU (2) RU2770016C2 (OSRAM)
SG (3) SG11201404477YA (OSRAM)
SI (2) SI3597038T1 (OSRAM)
SM (2) SMT202100401T1 (OSRAM)
WO (1) WO2013116609A1 (OSRAM)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018508224A (ja) * 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
JP2021505141A (ja) * 2017-12-05 2021-02-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用
JP2021519062A (ja) * 2018-03-24 2021-08-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ペプチド−ｍｈｃ複合体に対する治療用抗体を生成するための遺伝子改変非ヒト動物、ならびにその作製方法および使用方法
JP2021528057A (ja) * 2018-06-14 2021-10-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 免疫グロブリン重鎖コーディング配列におけるｄｈ−ｄｈ再構成が可能な非ヒト動物
JP2024129114A (ja) * 2016-04-04 2024-09-26 イーティーエッチ チューリッヒ タンパク質産生及びライブラリー生成のための哺乳類細胞株

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143472A2 (en) * 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
PT2564695E (pt) 2009-07-08 2015-06-03 Kymab Ltd Modelos animais e moléculas terapêuticas
CA3250882A1 (en) * 2010-08-02 2025-11-29 Regeneron Pharamaceuticals, Inc. Mice that Make Binding Proteins Comprising VL Domains
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
WO2013041844A2 (en) 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
KR102081657B1 (ko) 2011-12-20 2020-02-26 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
EP3597038B1 (en) * 2012-02-01 2021-04-21 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
HUE055617T2 (hu) 2012-06-12 2021-12-28 Regeneron Pharma Korlátozott immunglobulin nehézlánc lókuszokkal rendelkezõ, humanizált, nem humán élõlények
ES2678221T3 (es) 2013-02-20 2018-08-09 Regeneron Pharmaceuticals, Inc. Animales no humanos con secuencias de cadena pesada de inmunoglobulina modificadas
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
NL2013554B1 (en) 2013-10-01 2016-01-08 Kymab Ltd Animal models and therapeutic molecules.
BR112016021679A2 (pt) 2014-03-21 2018-12-04 Regeneron Pharmaceuticals, Inc. proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado.
BR112016021572A2 (pt) 2014-03-21 2017-10-03 Regeneron Pharma Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
EP3277823B1 (en) * 2015-04-03 2023-09-13 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
JP7324583B2 (ja) 2016-05-20 2023-08-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 複数のガイドｒｎａを使用して免疫寛容を破綻させるための方法
WO2018183946A1 (en) * 2017-03-30 2018-10-04 Utah State University Transgenic silkworms expressing spider silk
IL301137A (en) 2020-09-11 2023-05-01 Regeneron Pharma Identification and production of antigen-specific antibodies
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CN114645042A (zh) * 2020-12-18 2022-06-21 中国食品药品检定研究院 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法
CN114196626A (zh) * 2022-02-16 2022-03-18 北京国卫生物科技有限公司 脐带间充质干细胞及其分离培养扩增方法
CN118339300A (zh) * 2024-01-02 2024-07-12 江苏集萃药康生物科技股份有限公司 产生人源化抗体的动物模型及其构建方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143472A2 (en) * 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
WO2012018764A1 (en) * 2010-08-02 2012-02-09 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
US20120167237A1 (en) * 2009-07-08 2012-06-28 Kymab Limited Animal models and therapeutic molecules

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
EA007958B1 (ru) * 2000-08-03 2007-02-27 Терапеутик Хьюман Поликлоналз Инк. ТРАНСГЕННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ГУМАНИЗИРОВАННЫЙ ЛОКУС Ig, И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПОЛУЧЕНИЯ ТРАНСГЕННЫХ ЖИВОТНЫХ
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101016543A (zh) * 2000-11-17 2007-08-15 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
AU2002357410A1 (en) 2001-12-21 2003-07-09 Thromb-X Nv Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability and for the culture of adult stem cells
WO2003081993A2 (en) * 2002-03-22 2003-10-09 Origen Therapeutics Transgenic aves producing human polyclonal antibodies
ES2473596T3 (es) * 2003-07-15 2014-07-07 Therapeutic Human Polyclonals, Inc. Loci de inmunoglobulina humanizada
PT2767161T (pt) 2004-10-19 2018-04-20 Regeneron Pharma Método para gerar um animal homozigótico para uma modificação genética
CA2584814A1 (en) * 2004-10-22 2006-05-04 Therapeutic Human Polyclonals, Inc. Suppression of endogenous immunoglobulin expression in non-human transgenic animals
EP2505058A1 (en) * 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
CN101506235B (zh) * 2006-09-01 2012-07-25 人类多细胞株治疗学公司 人或人源化免疫球蛋白在非人转基因动物中增强的表达
BRPI0815848A2 (pt) * 2007-08-30 2017-06-06 The Burnet Inst composto, linhagem de célula que produz anticorpo estável, composição, métodos para modular uma resposta imune em um indivíduo e para tratar e/ou prevenir uma doença, usos de um composto e/ou uma composição e de células dendríticas ou precursores das mesmas, métodos para enriquecer e detectar células dendríticas ou um subconjunto ou precursores das mesmas, polipeptídeo, polinucleotídeo vetor, célula hospedeira, planta transgênica, animal não humano transgênico, extrato, processo para preparar um composto ou um polipeptídeo, população enriquecida de células dendríticas e/ou precursores das mesmas, população de célula dendrítica expandida e/ou precursores das mesmas, métodos para identificar uma molécula que se liga a um polipeptídeo e para triar quanto a um composto que se liga a um polipeptídeo, uso de um polipeptídeo, um polinucleotídeo, um vetor, uma célula hospedeira, uma planta transgênica, um extrato, uma população de célula e/ou uma composição, método para produzir um composto, e, kit.
CL2008002886A1 (es) * 2007-09-26 2009-12-04 Chugai Pharmaceutical Co Ltd Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
EP2556747B1 (en) * 2008-06-27 2020-12-02 Merus N.V. Antibody producing transgenic mice
EP2331689A4 (en) * 2008-08-29 2012-10-31 Symphogen As METHOD OF CLONING AVIAN ORIGIN ANTIBODIES
US9085795B2 (en) * 2009-02-04 2015-07-21 Molecular Innovations, Inc. Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
AU2011266843C9 (en) * 2010-06-17 2018-03-01 Kymab Limited Animal models and therapeutic molecules
SI2738258T2 (sl) * 2011-02-25 2023-05-31 Regeneron Pharmaceuticals, Inc. Miši ADAM6
MY172718A (en) * 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
KR102081657B1 (ko) * 2011-12-20 2020-02-26 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
EP3597038B1 (en) * 2012-02-01 2021-04-21 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
HUE055617T2 (hu) * 2012-06-12 2021-12-28 Regeneron Pharma Korlátozott immunglobulin nehézlánc lókuszokkal rendelkezõ, humanizált, nem humán élõlények
DK3766343T3 (da) * 2016-11-04 2022-06-20 Regeneron Pharma Ikke-humane dyr med et manipuleret immunoglobulin-lambda-letkædelocus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143472A2 (en) * 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
US20120167237A1 (en) * 2009-07-08 2012-06-28 Kymab Limited Animal models and therapeutic molecules
WO2012018764A1 (en) * 2010-08-02 2012-02-09 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FEATHERSTONE, K. ET AL.: "The Mouse Immunoglobulin Heavy Chain V-D Intergenic Sequence Contains Insulators That May Regulate O", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285（13）, JPN6016047421, 2010, pages 9327-9338 *
HAN, C., ET AL: "Comprehensive Analysis of Reproductive ADAMs: Relationship of ADAM4 and ADAM6 with an ADAM Complex R", BIOLOGY OF REPRODUCTION, vol. 80, JPN6016047420, 2009, pages 1001-1008 *
MURPHY D., BAC-BASED MODIFICATIONS OF THE MOUSE GENOME: THE BIG AND THE BACKWARD, WELLCOME TRUST A, JPN7016002559, 3 November 2009 (2009-11-03) *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018508224A (ja) * 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
JP2024129114A (ja) * 2016-04-04 2024-09-26 イーティーエッチ チューリッヒ タンパク質産生及びライブラリー生成のための哺乳類細胞株
JP2021505141A (ja) * 2017-12-05 2021-02-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用
JP7430636B2 (ja) 2017-12-05 2024-02-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用
JP2024036440A (ja) * 2017-12-05 2024-03-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用
US12356967B2 (en) 2017-12-05 2025-07-15 Regeneron Pharmaceuticals, Inc. Immunoglobulin lambda light chain and uses thereof
JP7765514B2 (ja) 2017-12-05 2025-11-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用
JP2021519062A (ja) * 2018-03-24 2021-08-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ペプチド−ｍｈｃ複合体に対する治療用抗体を生成するための遺伝子改変非ヒト動物、ならびにその作製方法および使用方法
JP2021528057A (ja) * 2018-06-14 2021-10-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 免疫グロブリン重鎖コーディング配列におけるｄｈ−ｄｈ再構成が可能な非ヒト動物
JP2022079617A (ja) * 2018-06-14 2022-05-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫グロブリン重鎖コーディング配列におけるｄｈ－ｄｈ再構成が可能な非ヒト動物
JP7182647B2 (ja) 2018-06-14 2022-12-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫グロブリン重鎖コーディング配列におけるｄｈ－ｄｈ再構成が可能な非ヒト動物
JP2024111243A (ja) * 2018-06-14 2024-08-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫グロブリン重鎖コーディング配列におけるｄｈ－ｄｈ再構成が可能な非ヒト動物

Also Published As

Publication number Publication date
BR112014018843A8 (pt) 2019-01-29
BR112014018843B1 (pt) 2024-02-20
JP7187615B2 (ja) 2022-12-12
ME03611B (me) 2020-07-20
CN106117364B (zh) 2021-08-31
IL261280B (en) 2019-08-29
SI2809150T1 (sl) 2019-11-29
HUE046744T2 (hu) 2020-03-30
PT2809150T (pt) 2019-12-09
IL268675B (en) 2020-11-30
ES2870703T3 (es) 2021-10-27
KR20140123983A (ko) 2014-10-23
SG10201606256TA (en) 2016-09-29
SI3597038T1 (sl) 2021-07-30
KR20190006029A (ko) 2019-01-16
MX2019002517A (es) 2019-06-17
SMT201900685T1 (it) 2020-01-14
JP6942757B2 (ja) 2021-09-29
JP2023014242A (ja) 2023-01-26
HUE055610T2 (hu) 2021-12-28
AU2013204758B2 (en) 2015-07-23
BR112014018843A2 (pt) 2017-07-04
JP7525579B2 (ja) 2024-07-30
SG10201913428QA (en) 2020-03-30
NZ627977A (en) 2016-06-24
JP2023168590A (ja) 2023-11-24
JP6698718B2 (ja) 2020-05-27
PL3597038T3 (pl) 2021-11-08
US20170094955A1 (en) 2017-04-06
ES2753774T3 (es) 2020-04-14
CY1122419T1 (el) 2021-01-27
EP2809150A1 (en) 2014-12-10
HRP20192218T1 (hr) 2020-03-06
RS59699B1 (sr) 2020-01-31
AU2013204758A1 (en) 2013-08-15
JP2021137030A (ja) 2021-09-16
RU2770016C2 (ru) 2022-04-14
AU2017251848A1 (en) 2017-11-16
PT3597038T (pt) 2021-05-10
RS62023B1 (sr) 2021-07-30
CN106117364A (zh) 2016-11-16
RU2664185C2 (ru) 2018-08-15
US20130212719A1 (en) 2013-08-15
CA2863175A1 (en) 2013-08-08
HK1202771A1 (en) 2015-10-09
DK3597038T3 (da) 2021-06-28
CY1124361T1 (el) 2022-07-22
PL2809150T3 (pl) 2020-04-30
MX2020003491A (es) 2022-10-25
US20210368751A1 (en) 2021-12-02
CN104202971A (zh) 2014-12-10
CN104202971B (zh) 2016-07-06
IL268675A (en) 2019-10-31
AU2015246154A1 (en) 2015-11-12
LT3597038T (lt) 2021-05-25
SG11201404477YA (en) 2014-08-28
JP2019170395A (ja) 2019-10-10
EP3597038A1 (en) 2020-01-22
NZ734504A (en) 2022-10-28
AU2017251848B2 (en) 2020-02-20
RU2018122695A3 (OSRAM) 2021-10-06
SMT202100401T1 (it) 2021-09-14
WO2013116609A1 (en) 2013-08-08
EP3597038B1 (en) 2021-04-21
DK2809150T3 (da) 2019-12-09
HRP20210987T1 (hr) 2021-09-17
IL233827A0 (en) 2014-09-30
IL261280A (en) 2018-10-31
JP2018075041A (ja) 2018-05-17
EP2809150B1 (en) 2019-09-18
NZ793447A (en) 2024-05-31
EP3912465A1 (en) 2021-11-24
AU2015246154B2 (en) 2017-11-23
NZ810648A (en) 2025-11-28
LT2809150T (lt) 2019-10-25
MX373286B (es) 2020-05-20
RU2014133653A (ru) 2016-03-20
NZ719228A (en) 2022-08-26
RU2018122695A (ru) 2019-03-06

Similar Documents

Publication Publication Date Title
JP7187615B2 (ja) Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物
JP7507823B2 (ja) ヒト化軽鎖マウス
JP7078400B2 (ja) Ｖｌドメインを含む結合タンパク質を作製するマウス
EP2858487A1 (en) Humanized non-human animals with restricted immunoglobulin heavy chain loci
HK40064569A (en) Humanized rodents that express heavy chains containing vl domains
HK40020364B (en) Humanized rodents that express heavy chains containing vl domains
HK40020364A (en) Humanized rodents that express heavy chains containing vl domains
HK1202771B (en) Humanized mice that express heavy chains containing vl domains
MX2014009300A (es) Roedores humanizados que expresan cadenas pesadas que contienen dominios vl.
BR122023011479B1 (pt) Método para produzir uma proteína de ligação ao antígeno humano que se liga a um antígeno de interesse, método para produzir uma célula es animal não humana geneticamente modificada, método para modificar um locus de imunoglobulina de cadeia pesada de uma célula es de camundongo e método para produzir uma sequência de nucleotídeos que codifica uma cadeia leve de imunoglobulina totalmente humana

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160113

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170508

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180209

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180219

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20180406

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20180528